Navigation Links
Dr. Lowell S. Kabnick First to Use New VenaCure® 1470nm Laser
Date:6/9/2011

MORRISTOWN, N.J., June 9, 2011 /PRNewswire/ -- Dr. Lowell S. Kabnick, MD, RPhS, FACS, FACPh, Director of NYU Vein Center and internationally recognized authority and pioneer in the field of vascular surgery, is once again leading the way with breakthrough techniques, being the first in the country to use the new VenaCure® 1470nm laser to treat varicose veins. The new laser uses a lower power output compared with other lasers resulting in effective vein closure.

The VenaCure 1470nm laser's light energy is accurately delivered through the NeverTouch® gold-tip fiber, and is more readily absorbed by the water in the blood and endothelial lining than with other wavelengths. The specially engineered fiber tip has a low power density that maximizes effectiveness and minimizes postoperative pain and bruising. The VenaCure 1470nm lasers are manufactured in AngioDynamics' Cambridge, U.K., facility, and have received the CE mark and 510k clearance.

Ongoing research studies have found excellent vein closure rates, minimal postoperative discomfort and bruising, and a clear reduction in symptom severity over the follow-up period.

"The 1470nm laser enables us to be more efficient during a procedure, we are able to treat veins much more efficiently, which ultimately improves the patients procedure experience," stated Dr. Kabnick. "That translates into quicker recovery for patients."

About Lowell S. Kabnick, MD, RPhS, FACS, FACPh

Lowell S. Kabnick, MD, RPhS, FACS, FACPh, a New York University Surgeon with offices in Manhattan and Morristown, NJ and Director of NYU Vein Center, is a world-renowned surgeon-teacher whose patient-centered approach to vein care has enabled the creation and improvement of many of today's most advanced noninvasive vascular surgery techniques. Recognized by his peers as an international leader in the diagnosis and treatment of venous disease, Dr. Kabnick was the first vascular surgeon in the United St
'/>"/>

SOURCE Lowell S. Kabnick
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Alzheimers Association Grant Furthers Successful Research at UMass Lowell
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
4. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Tainted Chinese Food Ingredients First Discovered in 2005
9. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
10. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Nektar Therapeutics (NASDAQ: ... positive results from its Phase 3 pivotal clinical ... recombinant factor VIII (rFVIII) treatment for hemophilia A ... its primary endpoint in reducing annualized bleed rates ... on-demand arm. Top-line results from the ...
(Date:8/21/2014)... , Aug. 21, 2014  Publicis Groupe ... Hartley , Managing Partner and Healthcare Industry Group Leader, ... 100, which recognizes the most inspiring people in the ... leaders in research and development, marketing, technology, creativity, strategy ... in 2006 as a partner in its leading Rosetta ...
(Date:8/21/2014)... BURLINGTON, Mass. , Aug. 21, 2014 /PRNewswire/ ... of COPD,  physicians in Brazil ... to follow clinical guidelines and commonly prescribe long-acting ... regimens, although they do so within current severe ... combinations (FDCs) that are expected to launch in ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Shannon Hartley Shines in PharmaVOICE 100 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
... Anpath Group, Inc.,(OTC Bulletin Board: ANPG), reported ... announced the selection of its,disinfectant, EnviroTru(TM) for ... (Metro). EnviroTru(TM) is a multi-purpose disinfectant ... also meets EPA requirements for,Toxicity Category IV ...
... of statins treated for 3 months with 200 mg/week mipomersen experienced ... continues to support mipomersen,s ... safety profile,- Isis hosting Analyst & Investor Day today - webcast live at 9:00 ... at http://www.isispharm.com , ...
Cached Medicine Technology:Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 2Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro) 3Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 2Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 3Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 4Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 5Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 6Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary 7
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues ... Massachusetts insurance companies have decided to limit coverage ... the Worcester Telegram, Blue Cross-Blue Shield of Massachusetts ... surgeries that involve morcellation as of September 1, ...
(Date:8/22/2014)... Bcl-2-like protein 11 (BIM) deletion in advanced ... shorter progression free survival (PFS) in epidermal growth ... chemotherapy treated Asian patients. Also, BIM deletion independently ... , The BIM protein can activate the programmed ... in cells. BIM deletion has been detected in ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Restore ... Sen and Dr. Samantha Pearson to help people discover ... avoid corrective vision surgery by instead improving their eyesight ... an investigative review. , “There’s a reason why ... in revenue each year—it’s because people just assume that ...
(Date:8/22/2014)... August 22, 2014 CarePoint Health ... in Internal Medicine, Geriatrics, Hospice and Palliative Care, ... Health Medical Group. Their system welcomes Dr. Reisner ... experienced physicians comprise CarePoint Health Medical Group, a ... Hudson County, representing a wide range of specialties. ...
(Date:8/22/2014)... Dayton Children's Hospital broke ground on a historic ... $141 million campus renewal. Renderings of the ... the public. , The new patient tower is part ... campus that meets the needs of patients, families and care ... embody Dayton Children’s unique patient care mission and offer places ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5
... be, presented at 59th Annual Meeting of the American Association for the ... ... Oct. 31 ,Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc.,(Nasdaq: ONXX ... 59th Annual Meeting of the American Association for the Study,of Live Diseases ...
... CHAPEL HILL, N.C., Oct. 31 Survival nurtures ... rely on their,customers, and employees, innovations in marketing, ... market share., Network with and learn from ... Annual Customer Experience Conference:,Integrated Customer Strategies that Enable ...
... a coma, 6 year chronic sciatica back pain, 15- and ... all these conditions were overcome using advanced magnetic therapy techniques ... ... Pennsylvania (PRWEB) October 31, 2008 -- Regenerating nerves, waking people ...
... published finds that, while about 40 percent of women ... that those issues are a source of significant personal ... Hospital (MGH) physician appears in the November issue of ... are common in women, but problems associated with personal ...
... Normal-weight women who carry out lots of vigorous exercise ... than those who don,t exercise vigorously. A study of ... BioMed Central,s open access journal Breast Cancer Research, ... a risk factor for the disease even in ...
... Nanoparticles Present in 4 out of 5,Sunscreens, Even ... N.Y., Oct. 30 Consumers Union,nonprofit publisher of ... 4 out of 5 sunscreens that claimed not ... urged the FDA to,require a full safety assessment, ...
Cached Medicine News:Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 2Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 3Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 4Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 5Health News:New Analyses Confirm Nexavar's Efficacy and Safety in Multiple Patient Subsets With Liver Cancer 6Health News:Survive the Economic Downturn Through Innovations in Integrated Customer Strategies 2Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 2Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 3Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 4Health News:BiomagScience Introduces Breakthrough Health Therapy Kits 5Health News:While prevalent, sexual problems in women not always associated with distress 2Health News:Vigorous activity protects against breast cancer 2Health News:Consumers Union Urges FDA to Conduct Full Scale Safety Review of Nanoparticles in Sunscreen 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: